Staphylococcal Toxins in Atopic Dermatitis and Eczema Herpeticum

  • End date
    Oct 16, 2023
  • participants needed
  • sponsor
    Poitiers University Hospital
Updated on 5 February 2021


Atopic dermatitis (AD) is the most common chronic inflammatory skin disease. Clinical studies have demonstrated a link between staphylococcal skin colonization and the pathogenesis of AD, but the implication of bacterial virulence factors remains largely uncharacterized. Finally, AD is often associated with herpes simplex skin infections. The aim of this project is to investigate the role of staphylococcal toxins in the exacerbation and maintenance of atopic skin inflammation and in the occurrence of infectious complications such as eczema herpeticum.

Condition bacterial toxin, Eczema, Eczema (Atopic Dermatitis - Pediatric), Staphylococcus aureus, cytokine, ATOPIC DERMATITIS, Eczema (Atopic Dermatitis), ATOPIC DERMATITIS, Dermatitis, Atopic, Dermatite Atopique, Eczéma (Dermatite Atopique), Dermatitis, Hand Dermatitis, Eczema (Atopic Dermatitis), Dermatitis, Atopic, Hand Dermatitis, Eczema (Atopic Dermatitis - Pediatric), Immune Response, Eczéma (Dermatite Atopique), Dermatite Atopique, s. aureus, cytokines, T Cells Subsets
Treatment Skin biopsies and blood samples
Clinical Study IdentifierNCT04274348
SponsorPoitiers University Hospital
Last Modified on5 February 2021


Yes No Not Sure

Inclusion Criteria

Patients with moderate AD (SCORAD between 25 and 50) or severe AD (SCORAD> 50)
Skin lesions in the forearms
Free subject, without neither guardianship, wardship nor subordination
Patient with Social Security
Informed and signed consent by the patient after clear and loyal information on the study

Exclusion Criteria

Age < 18 year-old
Patients with mild AD (SCORAD < 25)
Patients without skin lesions in the forearms
Patients treated with dermocorticoid or calcineurin inhibitor for less than two weeks
Patients under systemic treatment : Methotrexate, Ciclosporin, Mycophenolate Mofetil, Azathioprine, general corticosteroids for less than 4 weeks
Patients under biological treatment : Dupilumab for less than 5 half-lives
Patient without Social Security
Pregnant and nursing women
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note